Navigation Links
Valeritas Announces Appointment of New CFO
Date:3/17/2010

BRIDGEWATER, N.J., March 17 /PRNewswire/ -- Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that it has hired James E. Dentzer to serve as its Chief Financial Officer.

Dentzer brings a wealth of experience to Valeritas, with his most recent success as Chief Financial Officer of Amicus Therapeutics where he led the company in closing a Series D private financing and executing a successful IPO.

"We are extremely pleased to welcome Jim to the Valeritas executive team," said Kristine Peterson, Chief Executive Officer, Valeritas.  "He brings the financial experience Valeritas needs as we continue to advance the development of our products. This is an exciting stage in our company's growth and Jim's strong track record for taking companies public, helping organizations finance their growth, and his proven commercialization experience makes him ideal for our organization."  

"Joining Valeritas at this important time is very exciting," said Dentzer.  "With the company's strong set of current investors committed to the company's organizational needs, Valeritas is positioned to be a major player in the diabetes space.  I am proud to have joined an organization that can provide life-changing therapeutic options to people suffering with this condition."

Dentzer joined Amicus Therapeutics as Chief Financial Officer in October 2006 where he supported the organization through its IPO.  Prior to joining Amicus, he was Vice President and Corporate Controller of Biogen Idec and held various senior financial roles at E.I. du Pont de Nemours and Company.

About Valeritas, Inc.

Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes.  Valeritas' medical technologies portfolio is headlined by the h-Patch™ technology.  The first use of the h-Patch™ technology will be the V-Go™ Disposable Insulin Delivery Device for the simple delivery of basal-bolus therapy via a preset basal rate and on-demand bolus dosing around mealtimes.

In addition to the V-Go™, Valeritas' delivery technology portfolio includes the h-Patch™ for the delivery of other compounds beyond insulin, the Mini-Ject™ Pre-Filled Needle-Free Delivery System, and the Micro-Trans™ Microneedle Transdermal Delivery Patch.  These technologies, when combined with certain compounds, are designed to provide unique products that allow precise dosing in previously difficult to treat conditions.

Headquartered in Bridgewater, N.J., Valeritas operates its R&D and manufacturing in a state-of-the-art facility in Shrewsbury, Massachusetts. Valeritas primary investors include: MPM Capital, Pitango Venture Capital, Abingworth, US Venture Partners, Onset Ventures, Advanced Technology Ventures, HLM Venture Partners, CHL Medical Partners, and Kaiser Permanente Ventures.

SOURCE Valeritas, Inc.

Back to top
'/>"/>
SOURCE Valeritas, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Valeritas Hires Trade and Distribution Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
2. Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
3. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
4. Valeritas Announces Appointment of New CEO
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):